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ABSTRACT
Stress response gene ATF3 plays a pleiotropic role
in determining cell fate in response to mitogenic or
stress stimuli. An alternate promoter of the human
ATF3 gene (designated P1 in this study) has recently
been reported, which is located ~43.5kb upstream
of the previously reported P2 promoter. We showed
here that the P1 promoter is highly conserved
between human and mouse and is functional in
response to various stimuli, whereas the P1 pro-
moter was dominantly induced by serum and the
P2 promoter was more efficiently activated in
response to TGF-b and oncogenic HRAS. The P1
promoter contains multiple transcriptional start
sites, and the different 5’-UTRs markedly affected
their translation in response to stress. In human
prostate and Hodgkin Reed–Sternberg cancer cells
with elevated expression of ATF3, the P1 promoter
was constitutively activated and its chromatin struc-
ture was modified into active configuration. The dif-
ferential usage of alternate promoters of the ATF3
gene at both transcriptional and translational level
and the modification of chromatin structure may
provide a novel mechanism for expressing ATF3 in
determining cell fate during stress response and
cancer.
INTRODUCTION
An increasing number of studies demonstrate the existence
of alternate promoters for human genes and their
diﬀerential usage is one of important source for generating
protein and regulatory diversity (1,2). For example, tran-
scripts from alternate promoters are translated into dis-
tinct protein isoforms when their variant 50 exons contain
alternative ATGs, producing proteins with diﬀerent
N-termini or diﬀerent proteins. For many genes with mul-
tiple promoters, however, no variation in the resulting
proteins is generated, when a common downstream exon
contains the translation initiation site and generates
the same open reading frame (ORF). Some of these alter-
nate promoters have diﬀerent tissue speciﬁcity and devel-
opmental activity, such as the CYP19 gene encoding the
aromatase P450 (3) or glucokinase gene (4). Furthermore,
mRNA variants transcribed from the alternate promoter
cause diﬀerence of their translational eﬃciencies, since the
variant 50-UTRs regulate their secondary structure of
mRNAs, thus aﬀecting its stability and translation. The
usage of alternate promoters of genes has also been
reported to play role in stress response (5–8).
Activating transcription factor (ATF) 3 is a member of
the ATF/CREB family of basic-leucine zipper (b-Zip) type
transcription factors. Its mRNA level is low or undetect-
able in most cells, but is greatly induced by a variety of
stress signal (9–11, and references therein). This response
has dual eﬀects on cell fate, such as cell cycle arrest and
apoptosis (10–14), or cell survival and proliferation
(15–21). We have recently reported that ATF3 is induced
downstream of c-myc in serum induction (22), and other
laboratories showed that the ATF3 expression is elevated
in human prostate (23) and Hodgkin Reed–Sternberg cells
(24), and more recently in human breast cancer cells (25).
Furthermore, transgenic over-expression of ATF3 in basal
epithelial cells causes basal cell carcinoma in mouse (26).
ATF3 also plays role as a negative regulator of
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ical and pathological role of ATF3 in regulating the stress
response of cells to external stimuli.
The human ATF3 gene is mapped to chromosome
1q32.3 region, and is comprised of ﬁve exons spanning
 16kb (30). The putative gene promoter, designated P2
in this study, contains a TATA motif and many cis-
elements for binding of transcription factors responsible
for the regulated gene expression (11,21,30–34). More
recently, a large scale and genome-wide analysis of
50-end sequence of full-length cDNAs has identiﬁed a
novel upstream alternate promoter of the human ATF3
gene as deposited in Genbank (NM001030287) (35). We
also identiﬁed the transcripts in human and mouse cells
that contain various novel 50-UTR (DDBJ/EMBL/
GenBank with accession numbers AB291910, AB291911
and AB291912), but their functional and biological signif-
icance remains elusive.
In this report, we investigated the molecular and func-
tional properties of a novel upstream promoter, desig-
nated P1, of the human ATF3 gene. It is shown that the
P1 promoter is highly conserved between human and
mouse and is diﬀerentially used at both transcriptional
and posttranscriptional level in stress response. More
strikingly, the P1 promoter is constitutively activated in
human cancer cells with elevated expression of ATF3.
This study for the ﬁrst time describes evidence for the
diﬀerential usage of alternate promoters of the human
ATF3 gene, providing a novel insight into the molecular
mechanism by which ATF3 is induced in stress response
and cancer.
MATERIALS AND METHODS
Plasmids, antibodies andreagents
Plasmids encoding human HRAS wild-type and oncogenic
mutant 12V were purchased from Addgene, and expres-
sion plasmids for oncogenic Ras 61L mutant and HA-
Suv39 were gifts from Dr Nevins and Dr Jenuwein, respec-
tively. Antibodies used were as follow: rabbit anti-ATF3
(C19, sc-188), anti-H-Ras (F235, sc-29), anti-RNA-
polymerase II (N-20, sc-899) from Santa Cruz, anti-b-
actin (clone AC-74, A2228), anti-b-tubulin (clone
TUB2.1, T4026), anti-HA (clone HA-7) and anti-Flag
(clone M2) from Sigma, anti-Leo-1 (A300-175A) from
Bethyl, anti-H3-trimethyl-K4 (H3K4me3, ab8580)
and anti-H3-trimethyl-K9 (H3K9me3, ab8898) from
abcam, anti-acetyl-histone H3 (06-599) from Upstate.
Doxorubicin, thapsigargin, tunicamycin, etoposide were
from Sigma, methyl methanesulfonate (MMS) and H2O2
were nachalai tesque, recombinant human TGF-b was
from PeproTech. Other chemicals were reagents grade.
Cell cultureand treatments
Cell lines used in this study are HCT116 human colon
carcinoma cell, U2OS human osteosarcoma cell,
LNCaP, DU145, PC3 human prostate carcinoma cell
(ATCC), L428 and L540 Hodgkin Reed–Sternberg
cell (DSMZ, Germany), DAUDI human B cell and
MOLT4 human T cell (RIKEN, Japan), HaCaT human
keratinocyte (CLS, Germany). RAW264 is a mouse
macrophage cell line (RIKEN, Japan). Cells were cultured
in adequate media supplemented with 10% calf serum, 100
U/ml penicillin and 100 mg/ml streptomycin in a 5% CO2
atmosphere at 378C. For induction by serum or various
stimuli, cells were cultured in the presence of 0.5% serum
for 48h and induced by 20% serum, 100mg/ml MMS or
various agents. For expression of oncogene HRAS, neo-
mycin-resistant U2OS cells stably expressing mouse eco-
tropic retrovirus receptor were infected by pMX retroviral
vector encoding oncogenic mutants 12V, 61L, or normal
HRAS and selected with 2mg/ml puromycin. For transient
expression, plasmid DNA was vortex-mixed with
SuperFect (Qiagen) and transfected into cells according
to manufacture’s instruction.
Cellextract preparation andwestern blot analysis
Cells treated as indicated were harvested, washed in PBS,
and cell extracts were prepared as described (22). The
amounts of protein were measured by Lowry method
using bovine serum albumin as standard (36). Cell extracts
(20mg protein) were separated on an SDS–PAGE, trans-
ferred onto a nitrocellulose membrane, and subjected to
western blot using the protocol of ECL kit (Amersham).
RNA isolation andreverse transcription–PCR
Total RNA was isolated by acid-guanidinium method
using a kit from Qiagen. For detecting transcripts from
P1 or P2 promoters of ATF3 gene, RT–PCR of 1mg total
RNA was performed using a kit from TaKaRa. Primers
used were as follow: human P1 transcript, 50-AGGATGC
TCTGCTGTTTCCT-30 (forward) and 50-TTAGCTCTG
CAATGTTCCTTC-30 (reverse); human P2 transcript,
50-TGATGCAACGCTCTCCAAGC-30 (forward) and
50-TTAGCTCTGCAATGTTCCTTC-30 (reverse); mouse
P1 transcript, 50-AACAGGATCTCCCACAGGGT-30
(forward) and 50-GACAAAGGGTGTCAGGTTAG-30
(reverse); mouse P2 transcript, 50-CAGTGGAGCCAAT
CGGCTAA-30 (forward) and 50-GACAAAGGGTGTCA
GGTTAG-30 (reverse). Measurements of the ATF3 tran-
scripts from the P1 and P2 promoters or GAPDH were
also performed by quantitative RT–PCR. To this end, the
eﬃciency of PCR–ampliﬁcation of mRNA from each pro-
moter was determined by control reaction using the plas-
mid DNA for each transcript, and used for calibration
(Supplementary Figure S1). The data obtained were fur-
ther normalized with that of GAPDH. Primers used were
as follow: ATF3 (P1 transcript), 50-AGGATGCTCTGCT
GTTTCCT-30 (forward) and 50-GACAAAGGGCGTCA
GGTTAG-30 (reverse); ATF3 (P2 transcript), 50-TGATG
CAACGCTCTCCAAGC-30 (forward) and 50-CAGAAG
CACTCACTTCCGAG-30 (reverse); GAPDH, 50-TGAA
GGTCGGAGTCAACGGATTTGGT-30 (forward) and
50-TTGATTTTGGSGGGATCTCG-30 (reverse).
Primerextension analysis
Primer (50-GGGCAAGGTGCTGAAAATCC-30) com-
plementary to the region from +104 to +123 of
the human ATF3 mRNA with novel 50-UTR sequence
in database (NM001030287) was radiolabeled with
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32-g-ATP using T4 polynucleotide kinase, hybridized
with PolyA mRNAs from serum-treated HCT116, and
extended using AMV reverse transcriptase using a kit
from Promega. Extended products were resolved on an
8% polyacrylamide sequencing gel. The sequence ladder
was generated from the same primer using a template
plasmid DNA containing upstream promoter region of
the human ATF3 gene.
5’-Rapid amplification ofcDNA ends analysis
Human HCT-116 and mouse RAW264 cells were treated
with serum or MMS, and the 50-ends of the ATF3 mRNA
of the P1 promoter were determined by 50-rapid ampliﬁca-
tion of cDNA end analysis (50-RACE) using a kit from
Invitrogen. ATF3 cDNA was ampliﬁed by PCR using a
GeneRacer 50 primer or GeneRacer 50 nested primer and 30
primers speciﬁc for ATF3: human ATF3-30 reverse primer,
50-CCTGGATGTTGAAGCATCATTTTGA-30; mouse
ATF3-30 reverse primer, 50-TGGGATGAAGTGCTGGA
ACTC-30. Multiple transcription start sites (TSSs) of the
P1 promoter of human and mouse ATF3 genes have been
deposited in DDBJ/EMBL/GenBank with accession num-
bers AB291910 and AB291911, respectively.
RNAiexperiments
Mixtures of siRNA oligos (ﬁnal concentration 100 nM)
speciﬁc for the 50-UTR of P1 or P2 transcript isoforms
were transfected into HCT116 or LNCaP cells using
X-tremeGENE transfection reagent (Roche), or into
L428 and L540 Hodgkin Reed–Sternberg cells by electro-
poration as in ref. (24). HCT116 cells were then cultured
in medium with 0.5% serum for 24h, followed by stimu-
lation with 20% serum or 100mg/ml MMS. Sequences of
siRNAs for the P1 50-UTR were 50-AGAGAAAUCCUC
CUCUAUAUAGG-30 (83–105) and 50-UUUCAGCACC
UUGCCCCAAAAUC-30 (129–151), and those for the
P2 50-UTR were 50-GCCAGCCUGAGGGCUAUA
AAGG-30 (46–58), and 50-CUCGCCCGCCGGCCAGA
CAAACA-30 (190–212). Control RNAi (siCtl) was a silen-
cer negative control #1 (AM4611) from Ambion.
Luciferase assay
Reporter plasmid, pLuc-P1ATF3 was constructed by sub-
cloning a 2.1-kb fragment of the human ATF3 gene
upstream promoter from  2091 to +9 (major TSS as
+1) between Kpn1 and HindIII sites of pGL3 vector
(Promega). pLuc-P2ATF3 reporter plasmid containing a
1850-bp region of P2 promoter was as described (11). Cells
(5 10
4 cells) were transfected with 0.5mg each reporter
plasmid. At 16h posttransfection, cells were starved with
0.5% serum for 48h and then stimulated with 20% serum,
50mg/ml MMS, 20mg/ml etoposide, 50mMH 2O2,1 mM
doxorubicin, 2mM thapsigargin, 1mM tunicamycin or
100pM TGF-b For treatment with H2O2, cells were
exposed to 50mMH 2O2 in PBS for 1h, and then cultured
in fresh medium containing serum. After cell culture for
16h, extracts were assayed for the luciferase activity
as described (11), using a Dual Luciferase Reporter
Assay System according to the manufacture’s protocol
(Promega).
Translation in vitroand in vivo
cDNAs for ATF3 transcripts with various UTRs were
subcloned between Nhe1 and BamH1 sites of pcDNA3.1
expression vector. Each DNA (0.1mg) was transcribed
along with 0.2mg vector encoding HA-Suv39 as an inter-
nal control in 10mlo fin vitro TNT assay kit driven by T7
RNA polymerase, followed by translation. ATF3 protein
generated was quantitated by western blot and densito-
metric measurement. For the in vivo translation, the plas-
mid above (1mg each) encoding the ATF3 protein tagged
with Flag at the C-terminus was transfected into 293 cells
and the expression of ATF3 protein was measured by
western blot. Total RNA was also extracted, treated
with RNase-free DNase (Sigma) and assayed for ATF3
mRNA generated from the transgene by quantitative
RT–PCR. Primers used: 50-CTGCAGAAAGAGTCGG
AG-30 (forward, coding sequence of ATF3) and 50-TAG
AAGGCACAGTCGAGG-30 (reverse, BGH sequence of
the vector).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were per-
formed as described (22) according to the protocol sup-
plied by Upstate. ChIP DNA was detected using standard
PCR with the following primer pairs for the diﬀerent
regions of the ATF3 gene:  5-kb region, 50-TGGACAC
ACACACGGAAACT-30 (forward) and 50-GTCACATC
TTCCCATCTGATC-30 (reverse), the P1 promoter
region, 50-AGGATGATGGAAGGCTGTCA-30 (for-
ward) and 50-GTCACATCTTCCCATCTGATC-30
(reverse), +10-kb region, 50-TATGGGCTTTTGTTCG
GGTTC-30 (forward) and 50-TCAAAATGCGTGTGTG
TGTG-30 (reverse), +20-kb region, 50-AATGCCCTCA
CAGAAACACC-30 (forward) and 50-GTTAGGCAGG
AAGGGGAAAG-30 (reverse), +30-kb region, 50-GGT
GTGAATGTGCTTTGTGG-30 (forward) and 50-AGAA
TCGGAATGGCTGTGAG-30 (reverse), the P2 promoter
region (+40kb), 50-CGAACTTGCATCACCAGTGC-30
(forward) and 50-GGTCGTTTACTCCGTGTTGC-30
(reverse), +50-kb region, 50-ACATGTCCATCAGCTTC
CAG-30 (forward) and 50-CCACTGCTTGTGGATTAA
GG-30 (reverse), +55-kb region, 50-ACCTGTTCCCCAT
GGATGTA-30 (forward) and 50-TGTGTCAGGGAGCC
CAAATA-30 (reverse).
Statistical analysis
Multiple comparisons were evaluated by ANOVA fol-
lowed by Scheﬀe’s post hoc test. Data are presented as
mean   SD. Statistical signiﬁcance was assigned at the
level of P<0.05.
RESULTS
The upstream alternate promoter P1 isconserved between
human and mouse
It has recently been demonstrated that the human ATF3
gene contains an alternate promoter (Genbank accession
number NM001030287) (35). Figure 1B, upper panel,
showed two diﬀerent products were ampliﬁed from
1440 Nucleic Acids Research, 2009, Vol. 37,No. 5human cells by RT–PCR using two diﬀerent 50 primers,
which located at exon A-1 or canonical exon A
(Figure 1A), respectively. These bands were only
detected after the synthesis of the ﬁrst strand cDNA
using oligo-dT primer, indicating that they were derived
from the matured mRNA. In Figure 1B, lower panel, a
speciﬁc band was also ampliﬁed by RT–PCR of total
RNA of mouse RAW264 cells using a 50 primer located
at the  34.5-kb upstream of the mouse exon A. Sequence
analysis of these human and mouse transcripts revealed
that the longer bands correspond to those previously
reported (37,38), but the shorter ones contained novel
50-UTRs representing the transcripts from the upstream
promoter (DDBJ/EMBL/GenBank with accession
number AB291912 for mouse atf3). In Figure 1C,
the sequence comparison of the novel transcripts of
human and mouse showed that the junction of the
upstream exon A-1 and exon B are nearly identical.
Moreover, the nucleotide sequence alignment of the
human and mouse P1 promoter shows high homology
(Figure 2B). Taken together, these data indicate that
the novel P1 promoter is highly conserved between
human and mouse.
The upstream alternate promoter P1containsmultiple
TSSsin human andmouse
To determine the TSSs from the P1 promoter of the
human ATF3 gene, we ﬁrst performed a primer extension
analysis using mRNA from the serum-stimulated human
cells. As shown in Figure 2A, several extended products,
one major and at least three minor bands were identiﬁed,
indicating the presence of multiple TSSs from the P1 pro-
moter. We further performed a 50-RACE assay to deter-
mine the 50-end(s) of ATF3 transcripts. Figure 2B showed
that multiple TSSs determined by 5’-RACE coincided
with those by primer extension, indicating the isolation
of intact mRNA and the complete reaction by reverse
transcriptase. Multiple initiation sites were also observed
in the mouse P1 promoter (Figure 2B). From the sequence
homology of the P1 promoter and the multiple TSSs
between human and mouse, it is speculated that ATAAA
sequence at  30-bp upstream from the major start site
Figure 1. Conservation of the upstream alternate promoter of the ATF3 gene in human and mouse. (A) Schematic representation of the structure of
the human and mouse ATF3 genes. Exon A is further devided into A-1 and A corresponding to the novel promoter recently identiﬁed (35) and that
previously reported (27), respectively. (B) Total RNAs from serum-induced human HCT116 or mouse RAW264 cells were assayed for the expression
of transcripts containing the exon A-1 or A by RT–PCR. (C) Speciﬁc bands in (B) were subcloned, sequenced and the nucleotide sequences of the
junction between the exon A-1 and B of human and mouse are shown.
Nucleic Acids Research,2009, Vol.37, No. 5 1441is functional as putative TATA motif. Further, we
observed other binding motifs for ATF/CRE, AP1, p53,
E2F or NF-kB within the 2-kb upstream region of the P1
promoter (data not shown).
Differential response ofthe alternate promoters P1andP2
tovarious stimuli
Stress response gene ATF3 is activated by not only stress
but also mitogenic stimuli such as serum, epidermal
growth factor or ﬁbroblast growth factor (16,17). As
shown in Supplementary Figure S2, ATF3 mRNA and
protein was induced by serum and MMS treatment.
Figure 3A showed that both the P1 and P2 transcript iso-
forms were induced to a similar extent by MMS treatment.
In contrast, the P1 transcript was signiﬁcantly induced
by serum, whereas the induction of P2 transcript was
more rapid but decreased earlier than the P1 transcript.
To clarify the involvement of each promoter, we knocked
down the P1 or P2 transcript by RNA interference-
mediated gene silencing. As shown in Figure 3B, the
knockdown of the P1 or P2 transcript partially suppressed
the induction of ATF3 protein in response to MMS,
demonstrating the contribution of both promoters. In
contrast, in serum-stimulated cells, only the knockdown
of the P1 transcript signiﬁcantly reduced the ATF3 induc-
tion, clearly deﬁning the direct contribution of the P1 pro-
moter in serum induction. Next, we addressed if the P1
and P2 transcripts were induced by other stimuli.
Figure 3C showed that both transcripts were induced by
etoposide, H2O2, doxorubicin, thapsigargin and tunicamy-
cin. ATF3 is also induced by TGF-b (13) or oncogenic
HRAS (14), which mediates suppression of cell prolifera-
tion, tumor growth or cell senescence. Both the P1 and
P2 isoforms were also induced in HaCaT human kerati-
nocytes stimulated with TGF-b or in cells stably expres-
sing oncogenic HRAS 12V or 61L, but not normal
HRAS. The induction of the P2 transcript dominated
that of the P1 transcript in these cells. Further, we exam-
ined the activation of the P1 and P2 promoter by these
stimuli using a reporter assay. Figure 3D clearly showed
both the P1 and P2 reporter activities were induced in
response to these stimuli. Taken together, these data dem-
onstrate that the upstream alternate promoter P1 of
the ATF3 gene is activated at the transcriptional level
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1444 Nucleic Acids Research, 2009, Vol. 37,No. 5by various stimuli, but diﬀerently from the canonical P2
promoter.
Regulation oftranslation by 5’-UTRof thetranscripts from
the P1promoter
Figure 4A and Supplementary Figure S3 showed that the
50-UTR of the P1 transcripts has unique structural proper-
ties; multiple TSSs, less score of GC content ( 50%), and
ﬁve upstream AUG (uAUGs) compared to the P2 trans-
cripts; two TSSs, higher GC content ( 70%), and one
upstream AUG (uAUGs). Moreover, the 50-RACE analy-
sis revealed that multiple TSSs of the P1 promoter were
diﬀerently used in MMS-treated HCT116 cells from
serum-stimulated cells; the number ratio of clones
obtained were 6:12:12:0 (b:c:d:e) in MMS-cells compared
to 3:2:20:2 in serum response as in Figure 2B. To explore
the possible eﬀect of diﬀerent 50-UTRs on the transla-
tional eﬃciency, we performed a translational reporter
assay using the ATF3 expression plasmids containing dif-
ferent 50-UTR of the P1 and P2 transcripts. Figure 4B
showed that most of the P1 and P2 constructs generated
the ATF3 protein in vitro with an apparently comparable
eﬃciency, except for the long 50-UTR P2 transcript.
The relative eﬃciency of the in vivo translation of various
reporters in unstimulated 293 cells appeared to be similar
to those in vitro (Figure 4C). In contrast, in cells treated by
serum or MMS, the translation of the reporters P1-c, d, e
and P2-b were signiﬁcantly increased, whereas the trans-
lation of the P1-a and P1-b constructs was barely activated
(Figure 4D). This suggests the presence of not only the
inhibitory sequence(s) between a and c but also the
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Nucleic Acids Research,2009, Vol.37, No. 5 1445stimulatory element(s) in the shorter UTR forms, c, d and
e. Taken together, these data indicate that the structure of
50-UTRs of the P1 transcripts as well as the diﬀerential use
of TSSs signiﬁcantly aﬀects their translation in response to
stress.
Constitutive activation ofthe P1promoter in
ATF3-expressing human cancer cells
ATF3 is constitutively overexpressed in several forms of
human cancer cells such as prostate, Hodgkin disease
and mammary tumors (23–25), and the elevated ATF3
expression correlates to the cell proliferation, progression
and metastasis (23–25,39). To clarify the functional role
of alternate promoters in these cells, we examined the
expression of ATF3 from each promoter. Figure 5A
showed that, in human prostate cancer LNCaP and
Hodgkin Reed–Sternberg L428 and L540 cells, the
amount of ATF3 protein was increased as reported
(23,24). Most signiﬁcantly, the P1 transcript was domi-
nantly expressed in these cells compared to DU145 and
PC3 or DAUDI and MOLT 4 cells, demonstrating that
the P1 promoter is selectively activated. To further
clarify the actual involvement of each promoter, we
knocked down the P1 or P2 transcripts. Figure 5B
clearly showed the knockdown of the P1 transcript dras-
tically suppressed the expression of the ATF3 protein
along with the P1 transcript in LNCaP, L428 and L540
cells, whereas the P2 knockdown had only marginally
eﬀect. The data strongly support that the P1 promoter
has a direct contribution to the elevated expression of
ATF3 in these cancer cells. We next performed ChIP
assay to examine the association of RNA polymerase II
with the ATF3 gene locus. Figure 5C showed that, in
LNCaP cells, RNA polymerase II and Leo1, a component
of PAF1 complex in the elongating RNA polymerase II
(40), were clearly recruited through the P1 promoter to
downstream regions, compared to  5-kb region and the
control IgG, whereas the Leo1 signal peaked at around
+10-kb region. In contrast, DU145 cells that had lower
expression of ATF3 did not show signiﬁcant recruitment
of RNA polymerase II. The increased association of
RNA polymerase II to the P1 promoter region was
also observed in Hodgkin L428 cells (Supplementary
Figure S4). These data unambiguously indicate
the upstream P1 promoter of the ATF3 gene is constitu-
tively activated in human prostate and Hodgkin Reed–
Sternberg cells.
Chromatin modification of thehuman ATF3 gene
in cancer cells
Constitutive activation of the upstream P1 promoter
in cancer cells prompted us to examine the chromatin
modiﬁcations of the ATF3 gene promoter. As shown
in Figure 6A, antibodies against the pan-acetylated
histone H3 and trimethylated H3K4me3 eﬃciently immu-
noprecipitated the P1 promoter region in LNCaP and
Hodgkin 428 cells, compared to DU145 or DAUDI
cells. In contrast, no signiﬁcant H3K9 methylation was
observed at the ATF3 P1 promoter region in LNCaP
or L428 cells. As an inactivated gene control, the
ChIP signal of H3K9 methylation at the b-globin gene
promoter in L428 cells was also shown (Figure 6A).
e
m
p
t
y
U
T
R
(
-
) a bcdeab
A
T
F
3
 
 
P
r
o
t
e
i
n
 
/
 
m
R
N
A
 
P1 P2
4
3
2
1
0
P1 P2
U
T
R
 
(
-
)
abcd eab
e
m
p
t
y
ATF3
C
e
m
p
t
y
U
T
R
(
-
) a bcdeab
A
T
F
3
 
 
P
r
o
t
e
i
n
 
/
 
m
R
N
A
 
P1 P2
12
9
6
3
0
e
m
p
t
y
U
T
R
(
-
) a bcdeab
A
T
F
3
 
 
P
r
o
t
e
i
n
 
/
 
m
R
N
A
 
P1 P2
8
6
4
2
0
D Serum MMS
Unstimulated
Figure 4. Continued.
1446 Nucleic Acids Research, 2009, Vol. 37,No. 5Figure 6B and Supplementary Figure S5 further
showed that the signiﬁcant pan-acetylation and K4 tri-
methylation of H3 were detected from the P1 pro-
moter to +10-kb region compared to other region in
LNCaP and L428 cells, respectively. Taken together, the
P1 promoter of the ATF3 gene in LNCaP and Hodgkin
L428 cells has an active chromatin conﬁguration asso-
ciated with the histone H3 acetylation and H3K4
trimethylation.
DISCUSSION
In the present report, we described the structural and func-
tional properties of the upstream alternate promoter P1 of
the human ATF3 gene. The P1 promoter is used diﬀerently
from the P2 promoter at the transcriptional and transla-
tional level in stress response. Moreover, it is constitu-
tively activated in human cancer cells associated with the
active chromatin conﬁguration, as a consequence, fol-
lowed by the elevated expression of ATF3.
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Nucleic Acids Research,2009, Vol.37, No. 5 1447Kimura et al. (35) reported that at least 52% of the
human genes contain putative alternative promoters,
with 3.1 alternative promoters per gene on average, and
the genes subject to regulation by alternative promoters
are enriched in those encoding signal transduction-related
proteins. Indeed, the ATF3 gene encodes a transcription
factor that is induced and plays role in various stress
response and signaling. The P1 promoter of the ATF3
gene was highly conserved between human and mouse,
which localizes  43.5-kb and  34.5- kb upstream of the
previously reported canonical promoter P2 (30), respec-
tively. The P1 promoter has several properties that are
conserved between human and mouse. (i) Sequence of
the promoter region as well as the junction of exon A-1
and B are highly conserved (Figure 1C and 2B). The puta-
tive TATA motif is localized  30 base upstream from the
major TSS, and other binding motifs for AP1, ATF/
CREB, NF-kB, E2F, or p53 are conserved. (ii) Multiple
TSSs are present in the human and mouse genes. (iii) The
P1 promoter has less stretch of CG dinucleotides, whereas
the P2 promoter contains at least three CpG islands within
the 2-kb region of the promoter. This structural diﬀerence
between the P1 and P2 promoters is of intrigue, because
there is one CpG-island-containing promoter per 2.6
CpG-less alternate promoters (35). Overall, the structural
properties of the P1 promoter strongly support that it is
evolutionally conserved between human and mouse, and
has distinct control mechanism.
The P1 promoter of the ATF3 gene in human cells was
activated by various stimuli including serum, DNA
damage and oxidoreductive stress, and the extent of the
P1 promoter activation was comparable to or exceeded
that of the P2 promoter (Figure 3). Indeed, the 50-ﬂanking
region of the P1 promoter contains several motifs for tran-
scription factors involved in the signaling of stress stimuli,
including the binding motifs for ATF/CRE, AP1, NF-kB,
E2F, c-Myc or p53. Whereas the signiﬁcance and implica-
tion of these motifs in each stress response was not
addressed in this report, it is also possible that a
common motif(s) in the ATF3 gene locus confers stress
response on both the P1 and P2 promoters. This is an
important issue and must await further study.
Various 50-UTRs of the P1 transcripts contain the fea-
tures of poorly translated mRNA, that is relatively long
50-UTR with multiple upstream AUGs (uAUGs) and
upstream ORFs (Figures 2B and 4A). These features are
often found in mRNAs encoding regulatory proteins like
proto-oncogenes or growth factor (41), consistent with
biological role of the ATF3 gene. In our translational
reporter assay, however, sequential mutations of uAUGs
in the 50-UTR of the P1 transcrips had no signiﬁcant eﬀect
on their translation (data not shown). The assay revealed
the presence of the inhibitory region in the longest 50-UTR
as well as the stimulatory element(s) in the shorter
50-UTRs, implicating a role of trans-acting factor(s) inter-
acting with these element(s) in the 50-UTR in stress
response. The identiﬁcation of such factor(s) and the cor-
responding cis-element(s) is an important issue of further
study. It should be noted that the present study employed
the reporters containing only the diﬀerent 50-UTRs, since
the P1 and P2 transcripts have the common sequence from
the coding through the 30-UTR (NM_001030287 and
NM_001674). However, it is possible that the 30-UTR
may contribute to the regulation, since 30-UTR is well
known to aﬀect the translational eﬃciency in vivo.
More importantly, the 50-RACE analysis revealed the dif-
ferential usage of TSSs in MMS- and serum-treated cells.
Thus, it is highly likely that the selection or shift of the
TSSs within the P1 promoter also regulates the eﬃciency
of translation in vivo.
Early studies showed that the ATF3 induction corre-
lates with cell-detrimental outcome such as cell cycle
arrest or apoptosis, thus providing an idea that it is
death factor (9–12). However, ATF3 is also implicated
in cell proliferation (13,15,18,22), transformation (19),
cell survival (20,21) and tumorigenesis (14,23–26). Our
present study demonstrated for the ﬁrst time that the P1
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1448 Nucleic Acids Research, 2009, Vol. 37,No. 5promoter is constitutively activated in human cancer cells
with the elevated expression of ATF3 protein. In LNcaP
and Hodgkin cancer cells, the chromatin structure of the
P1 promoter region is remodeled and ﬁxed to an active
open state through the histone modiﬁcation, including
histone H3 acetylation and H3K4 trimethylation
(Figure 6). As in Figure 3A, the serum response of the
P2 promoter was more rapid but suppressed earlier than
the P1 promoter. It is speculated that the P2 promoter
responds to serum, but is suppressed by the transcription
from the upstream promoter P1 through a mechanism
called delayed transcriptional interference (42), while it is
also possible that the splicing of the transcripts is diﬀer-
ently regulated. At this moment, however, it is not known
to what extent these mechanisms could be applied to con-
stitutive activation of the P1 promoter in LNCaP and
Hodgkin cancer cells. It is also unlikely that cis-element(s)
of the promoter responsible for serum response is the only
mechanism by which the P1 promoter is constitutively
activated in cancer cells, since the P2 promoter is induced
by serum in rat ﬁbroblasts via ATF/CRE motif (22),
and the reporter activity driven by the P2 promoter was
activated by serum as eﬃciently as the P1 promoter
(Figure 3D).
In conclusion, the present study for the ﬁrst time
described the molecular and functional properties of the
upstream alternate promoter P1 of the stress response
gene ATF3. Of intrigue, the expression from the P1
promoter is regulated at both the transcriptional and
translational levels, and is constitutively activated with
altered chromatin structure in human cancer cells. The
diﬀerential usage and regulation of the alternate promo-
ters of the human ATF3 gene adds an important dimen-
sion to the control mechanism by which it plays dual
role in determining cell fate during stress response and
oncogenesis.
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